You are viewing: Japan Plasma Fractionation Market analysis
Part of: Plasma Fractionation Market (Global)

The Japan Plasma Fractionation Market was valued at $875.7 Million in 2026 and projected to reach to $1328.1 Million by 2031, representing a compound annual growth rate of 8.7%. Japan's plasma fractionation market is positioned for sustained growth through 2031, driven by demographic shifts and rising prevalence of hematological and immunological disorders.

Japan Plasma Fractionation Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

Japan Plasma Fractionation Market Trends and Insights

  • Japan's aging population and rising prevalence of bleeding disorders, immunodeficiencies, and thrombotic conditions are driving demand for plasma-derived therapies.
  • Japan's advanced healthcare infrastructure and stringent regulatory standards position the country as a key market for high-quality plasma fractionation products. The Japanese market benefits from strong government support for plasma self-sufficiency and domestic collection initiatives.
  • Japan's pharmaceutical companies and plasma collection centers are investing in advanced fractionation technologies to meet growing clinical demand.
  • Between 2026 and 2031, Japan is expected to see increased adoption of immunoglobulins, clotting factors, and albumin products across hospitals and specialty clinics. Japan's competitive landscape includes both domestic manufacturers and international players, with regulatory approval pathways favoring products meeting Japan's rigorous safety and efficacy standards.
  • The market's 8.7% compound annual growth rate reflects Japan's commitment to self-sufficiency in plasma products and expanding treatment accessibility across its aging demographic..

Key Market Statistics

  • CAGR (2026-2031) 8.7% CAGR
  • Market Size, 2026 ~USD 875.7 Million
  • Forecast, 2031 ~USD 1328.1 Million
  • Country Japan

Japan Plasma Fractionation Market Overview

Aging Population Driving Demand :

Japan's rapidly aging demographic, with over 29% of the population aged 65+, is significantly increasing demand for plasma-derived therapies to treat age-related bleeding disorders, immunodeficiencies, and thrombotic conditions.

Advanced Healthcare Infrastructure :

Japan's world-class healthcare system, equipped with cutting-edge diagnostic and treatment facilities, supports widespread adoption of plasma fractionation products and ensures high standards of patient care and product quality.

Stringent Regulatory Standards :

Japan's rigorous regulatory framework, enforced by the PMDA (Pharmaceuticals and Medical Devices Agency), ensures only high-quality plasma fractionation products enter the market, building strong consumer trust and market stability.

Strong Market Growth Trajectory :

With a CAGR of 8.7% from 2026 to 2031, Japan's plasma fractionation market is expanding faster than the global average of 7.6%, reflecting increasing clinical adoption and healthcare investment in the region.

Japan Plasma Fractionation Market Dynamics

  • The market's expansion from USD 875.7 million in 2026 to USD 1,328.1 million by 2031 reflects strong demand for albumin, immunoglobulins, and clotting factors across hospitals and specialty clinics. Key growth catalysts include Japan's commitment to advanced healthcare delivery, increasing awareness of rare bleeding disorders, and expanding reimbursement coverage for plasma-derived therapies.
  • The country's robust pharmaceutical manufacturing capabilities and export-oriented biotech sector further strengthen market competitiveness and innovation in plasma fractionation technologies..

Market Ecosystem

logo-mobile

PLASMA FRACTIONATION MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
company logo
Implemented the Horizon 2 plasma fractionation process at its Kankakee facility to improve immunoglobulin recovery from donated plasma Higher immunoglobulin yield | Improved plasma utilization | Greater production efficiency | Increased supply capacity
company logo
Implemented process improvements through its One Day Batch Release program at plasma-derived therapy manufacturing sites to accelerate batch release Faster batch release | Improved manufacturing efficiency | Shorter lead times | Faster product availability

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

Related Ecosystem

Biotechnology

Top Technologies
  • Reagents
  • Polymerase Chain Reaction (PCR)
  • Stem Cells
  • Assay Kits
  • Flow Cytometers
Top Companies
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Agilent Technologies, Inc.
  • Bio-Rad Laboratories, Inc.

    Pharmaceuticals

    Top Technologies
    • Bioreactors
    • Analytical Testing
    • Bioanalytical Testing Services
    • Cell Counters
    • Data Management Services
    Top Companies
    • Thermo Fisher Scientific Inc.
    • Merck KGaA
    • SANOFI
    • Pfizer Inc.
    • NOVARTIS

      Key Takeaways

      • Japan's plasma fractionation market is valued at USD 875.7 million in 2026 and will reach USD 1,328.1 million by 2031, representing an 8.7% CAGR.
      • Japan's aging population and high prevalence of chronic conditions drive sustained demand for immunoglobulins, clotting factors, and albumin therapies.
      • Japan's government-backed plasma self-sufficiency initiatives and domestic collection programs strengthen the country's market position and reduce import dependency.
      • Japan's stringent regulatory environment and advanced healthcare infrastructure create barriers to entry but ensure product quality and clinical efficacy standards.

      Plasma Fractionation Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment SCIG (Type)
      Forecast Period 2026-2030
      Growth Rate CAGR of 7.6% from 2026 to 2030
      Largest Segment THERAPEUTICS (Application)
      Market Size Base Year (Billions) ~USD 36.46 (2026)
      Revenue Forecast (Billions) ~USD 48.87 (2030)
      Segments Covered Product, Type, Application, Therapeutic Area, End User

      Japan Plasma Fractionation Market Report Segmentation

      5 segment dimensions are covered across the global market.

      By Product

      • Albumin
      • Coagulation Factor Concentrates
      • Immunoglobulins
      • Other Plasma Products
      • Protease Inhibitors

      By Type

      • Factor Ix
      • Factor Viii
      • Factor Xiii
      • Fibrinogen Concentrates
      • Ivig
      • Other Coagulation
      • Other Coagulation Factor Concentrates
      • Other Immunoglobulins
      • Prothrombin Complex Concentrates
      • Prothrombin Factor Concentrates
      • Scig
      • Von Willebrand Factor

      By Application

      • Academics & Preclinical Research
      • Therapeutics

      By Therapeutic Area

      • Critical Care
      • Hemato-Oncology
      • Hematology
      • Immunology
      • Neurology
      • Other Therapeutic Areas
      • Pulmonology
      • Rheumatology

      By End User

      • Home Care Settings & Infusion Centers
      • Hospitals & Specialty Clinics
      • Other End Users

      Target Audience

      • Pharmaceutical Manufacturers : Plasma fractionation companies need Japan-specific market data to optimize product portfolios, plan manufacturing capacity, and develop localized commercialization strategies for this high-growth market.
      • Healthcare Investors & PE Firms : Investment professionals require detailed Japan market analysis to evaluate acquisition targets, assess portfolio company performance, and identify emerging biotech opportunities in plasma therapeutics.
      • Hospital & Clinical Networks : Healthcare providers need market insights to forecast plasma product demand, optimize procurement strategies, and ensure adequate supply of critical therapies for patient populations.
      • Regulatory & Compliance Consultants : Consultants advising companies on Japan market entry require comprehensive regulatory landscape data, PMDA guidelines, and compliance requirements specific to plasma fractionation products.
      • Market Research & Strategy Teams : Corporate strategists and business development teams need Japan-focused market intelligence to support competitive analysis, market positioning, and long-term growth planning in Asia-Pacific.

      Reasons to Buy this Report

      • Japan-Specific Market Sizing : Access precise market valuations and forecasts tailored exclusively to Japan, enabling accurate budgeting, investment decisions, and competitive positioning in this high-value Asian market.
      • Demographic & Clinical Insights : Understand Japan's unique aging population dynamics and disease prevalence patterns driving plasma fractionation demand, allowing targeted product development and market entry strategies.
      • Regulatory & Compliance Guidance : Gain detailed knowledge of Japan's PMDA requirements and stringent quality standards, reducing market entry risks and accelerating product approvals for plasma-derived therapeutics.
      • Competitive Landscape Analysis : Identify key players, market share distribution, and competitive strategies specific to Japan's plasma fractionation sector to inform partnership and acquisition opportunities.
      • Growth Opportunity Identification : Discover high-potential segments within Japan's market, including emerging therapies for rare disorders and underserved patient populations, to maximize revenue and market penetration.

      Frequently asked questions

      What is the current size of Japan's plasma fractionation market?

      Japan's plasma fractionation market is valued at USD 875.7 million in 2026 and is projected to grow to USD 1,328.1 million by 2031.

      What is the expected growth rate for Japan's plasma fractionation market?

      Japan's plasma fractionation market is expected to grow at a compound annual growth rate (CAGR) of 8.7% from 2026 to 2031.

      What factors are driving growth in Japan's plasma fractionation market?

      Japan's aging population, rising prevalence of bleeding disorders and immunodeficiencies, government plasma self-sufficiency initiatives, and advanced healthcare infrastructure are key growth drivers.

      Which plasma products are most in demand in Japan?

      Immunoglobulins, clotting factors, and albumin products are among the most demanded plasma fractionation products in Japan's healthcare system.

      How does Japan's regulatory environment affect the plasma fractionation market?

      Japan's stringent regulatory standards ensure high product quality and clinical efficacy, creating barriers to entry but establishing Japan as a premium market for plasma-derived therapies.

      RESEARCH METHODOLOGY

      This research study extensively used secondary sources, directories, and databases to identify and collect valuable information for analyzing the global plasma fractionation market. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market's growth prospects. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size..

      Secondary Research

      The secondary sources for this research study include publications from government sources, such as FDA/CBER, EMA, WHO, and national health and regulatory authorities; industry associations, such as the Plasma Protein Therapeutics Association (PPTA), the International Plasma and Fractionation Association (IPFA), and AABB; and commercial databases, such as Bloomberg Business, D&B, Factiva, and relevant trade databases. Additional sources include white papers, annual reports, company house documents, investor presentations, scientific and clinical publications, regulatory filings, patent databases, and product and clinical trial databases. Secondary research was used to identify and collect information for the extensive, technical, market-oriented, and commercial study of the plasma fractionation market. It was also used to obtain important information about key players, market classification, segmentation according to industry trends, the bottom-up approach, and key developments from market and technology perspectives. Secondary data was also used to assess plasma collection capacity, fractionation and manufacturing infrastructure, product portfolios, regulatory frameworks, trade patterns, clinical applications, and regional market trends. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.

      Primary Research

      In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess the market’s prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information.

      Plasma Fractionation Market
 Size, and Share

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      The top-down and bottom-up approaches were used to estimate & validate the total size of the plasma fractionation market. These methods were also used extensively to estimate the size of various market segments.

      Plasma Fractionation Market : Top-Down and Bottom-Up Approach

      Plasma Fractionation Market Top Down and Bottom Up Approach

      Data Triangulation

      After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from both the demand and supply sides.

      Market Definition

      Plasma-derived therapies are medical treatments based on human plasma. Plasma is the largest component of human blood and contains water, salts, enzymes, antibodies, and other proteins. Before it can be used in medical therapies, it undergoes a fractionation process in which the relevant proteins are separated. Plasma-derived therapies are used to treat a wide range of (rare) diseases, from bleeding disorders and inhibitor deficiencies to primary and secondary immunodeficiencies.

      Key Stakeholders

      • Plasma Fractionation Product Manufacturers and Distributors
      • Pharmaceutical and Biotechnology Companies
      • Healthcare Service Providers (including Hospitals and Clinics)
      • Research and Development (R&D) companies
      • Academic Institutes
      • Government Associations
      • Market Research and Consulting Firms
      • Venture Capitalists and Investors

      Report Objectives

      • To define, describe, and forecast the plasma fractionation market based on product, application, therapeutic area, end user, and region
      • To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
      • To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall plasma fractionation market
      • To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
      • To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
      • To strategically profile the key players in the plasma fractionation market and comprehensively analyze their core competencies and market rankings
      • To track and analyze competitive developments such as product launches, acquisitions, expansions, agreements, partnerships, and collaborations in the plasma fractionation market
      • To benchmark players within the plasma fractionation market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product/service strategy

      Available customizations:

      With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for this report:

      Product Analysis

      • Further breakdown of the Rest of Europe Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Asia Pacific Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Latin America Plasma Fractionation Market, by country
      • Further breakdown of the Rest of Middle East Plasma Fractionation Market, by country

      Company Information

      • Detailed analysis and profiling of additional market players (up to five)

      Get the Full Plasma Fractionation Market Report

      Full forecast, segment splits, and company analysis for all Plasma Fractionation Market.

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      DMCA.com Protection Status